A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Chlamydia and Gonorrhea Positivity Surges in Women Ages 18-30 Years, Finds Quest Diagnostics Health Trends Study

Analysis of 18 Mil De-identified Lab Tests Also Reveals Shift in Positivity Rate Toward Older Women, with More Females “Aging Out” of Annual Screening Guidelines That End at Age 25

September 3, 2020

The rate at which women 18-30 years of age tested positive for the two most common reportable sexually transmitted infections grew by double digits between 2010 and 2017, finds an analysis of nearly 18 million de-identified test results from Quest Diagnostics.

Quest Diagnostics notes the new Health Trends® study from Quest Diagnostics is believed to be one of the largest to examine rates of clinical laboratory test results for Chlamydia trachomatis(chlamydia) and Neisseria gonorrhoeae (gonorrhea) on a national scale. The study examined 17,794,680 co-testing laboratory results for both infections from females aged 12–30 years tested at Quest Diagnostics during 2010–2017.

The study is available in the American Journal of Preventive Medicine (AJPM) online ahead of print here.

In addition to showing sharp increases in the positivity rates of chlamydia and gonorrhea, the study also found that the positivity rates of both infections shifted toward older ages over the eight-year study period. This observed shifts in age-based risk is significant because it raises the prospect that current medical guidelines for screening are not aligned with the sexual behaviors of, and associated risk of infection in, women in the United States.

Guidelines from the Centers for Disease Control and Prevention (CDC) and the U.S. Preventive Services Task Force (USPSTF) recommend annual screening for both infections in all sexually active women younger than 25 years of age. Screening in women 25 years of age and older is recommended only for those with certain risk factors, such as a new or multiple sexual partners or inconsistent condom use.

Yet, according to the study, the positivity rate for chlamydia for 27-year-old women in 2017 (3.5%) was the same as the positivity rate for 24-year-old women in 2010. A similar dynamic was observed for gonorrhea infections, with the positivity rate in 30-year-olds in 2017 (0.5%) identical to that found in 23-year-olds in 2010.

Overall, the peak age of positivity for both infections increased by one to two years and, in test results at the farthest distribution, by 3 to 7 years for chlamydia and gonorrhea respectively, over the eight-year study period.

Infections with chlamydia and gonorrhea often lack symptoms and, left untreated, may result in pelvic inflammatory disease and infertility.

“Our Health Trends data shows that sexually transmitted infections do not discriminate by age,” said lead researcher Harvey W. Kaufman, M.D., Senior Medical Director and Director, Health Trends Research Program at Quest Diagnostics. “When a sexually transmitted infection goes undetected and untreated, the result can be long-term health problems such as infertility and unknowing transmission of the infection to others. Sexual behaviors have changed in the United States, and guidelines need to reflect that women may be spending longer periods of time being sexually active and with more partners prior to childbearing than in the past.”

Among the key findings:

  • The annual chlamydia positivity rate increased by 18 percent overall (4.9% in 2010 to 5.8% in 2017), while annual gonorrhea positivity increased by 33 percent overall (0.7% in 2010 to 0.9% in 2017).
  • Although women ages 18-24 were more likely to test positive for either infection, women 25-30 years of age experienced a higher increase over the 8-year period. Among women 25-30 years of age, the positivity rate increased by 50 percent (from 2.2% in 2010 to 3.3% in 2017), compared to women in the 18-24 age group, at 21 percent (6.1% to 7.4%).
  • Among the youngest (12-17) age group, the positivity rate declined 17 percent for chlamydia (8.9% in 2010 to 7.4% in 2017) and 14 percent for gonorrhea (1.33% in 2010 to 1.17% in 2017).

“Our analysis raises the possibility that some women in the United States are prematurely aging out of access to annual screening, given current guidelines,” said co-author Damian P. Alagia, III, M.D., Senior Medical Director of Woman’s Health for Quest Diagnostics. “As such, women over the age of 24 years can only access testing if they are symptomatic or labeled ‘high risk’ by their healthcare provider following a potentially uncomfortable dialogue about their sexual behavior. Given changing sexual mores, a more thoughtful and inclusive population screening approach supporting screening access for women above the age of 24 years is overdue.”

The study, “Chlamydia and Gonorrhea: Shifting Age-Based Positivity among Young Females, 2010-2017,” is available at: https://www.sciencedirect.com/science/article/pii/S0749379720302713#!

Approximately 1,760,000 cases of chlamydia and 583,000 cases of gonorrhea infections were reported to the Centers for Disease Control and Prevention in 2018.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

SABIC advises the project was initiated together with the dialysis department at Jessa Hospital, one of the largest non-university medical cluster in the Limburg region of Flanders, Belgium.
Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines

By using this website you agree to accept Medical Device News Magazine Privacy Policy